Vray ipo software#
MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. The Company offers radiation therapy technology combined with magnetic resonance imaging. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. Xie will receive the compensation paid to all non-employee directors of the Company. Xie and the Company that would require disclosure under Item 404(a) of Regulation S-K.Īs a non-employee director, Dr. Additionally, there is no transaction between Dr. Xie and any other person to which he was elected as a director of the Company. There is no arrangement or understanding between Dr. Xie is qualified to serve on our board based on his extensive expertise in the healthcare industry. from The Wharton School, University of Pennsylvania. from The City University in New York, and an M.B.A. from Tianjin University in China, a Ph.D. From 1999 to 2001, he served as Project Leader and Senior Scientist for Boehringer Ingelheim Pharmaceuticals, Inc.
![vray ipo vray ipo](https://g.foolcdn.com/editorial/images/609495/gloved-hand-holding-a-beaker-full-of-money.jpg)
Xie served as an Equity Analyst for Delaware Investments, an asset management firm, from June 2002 to July 2005. From 2005 to 2008, he served as Principal and subsequently Managing Director for Great Point Partners, a healthcare hedge fund. Xie served as Healthcare Sector Head for Scopia Capital, a global hedge fund. He co-founded and served as Portfolio Manager for Locust Walk Capital from April 2010 to February 2012. Xie served as Managing Partner for Kinglington Capital, an investment company. Xie has served as President of Healthcare Holdings for Fosun Group, a Chinese international conglomerate and investment company, and Chief Representative of Fosun, NY since March 2015.